

13. Seguin JC, Walker RD, Caron JP, Kloos WE, George CG, Hollis RJ, Jones RN, Pfaller MA. Methicillin-resistant *Staphylococcus aureus* outbreak in a veterinary teaching hospital: potential human-to-animal transmission. *J Clin Microbiol.* 1999 May;37(5):1459-63.
14. Weese JS, Rousseau J, Traub-Dargatz JL, Willey BM, McGeer AJ, Low DE. Community-associated methicillin-resistant *Staphylococcus aureus* in horses and humans who work with horses. *J Am Vet Med Assoc.* 2005 Feb 15;226(4):580-3.
15. Weese JS, Archambault M, Willey BM, Hearn P, Kreiswirth BN, Said-Salim B, McGeer A, Lishoshvay Y, Prescott JF, Low DE. Methicillin-resistant *Staphylococcus aureus* in horses and horse personnel, 2000-2002. *Emerg Infect Dis.* 2005 Mar;11(3):430-5.
16. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome *mec* driven by a novel cassette chromosome recombinase, *ccrC*. *Antimicrob Agents Chemother.* 2004 Jul;48(7):2637-51.
17. Hiramatsu KI, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol.* 2001 Oct;9(10):486-93..
18. Murchan S, Kaufmann ME, Deplano A, de Ryck R, Struelens M, Elsbeg Zin C, Füssing V, Salmenlinna S, Vuopio-Varkila J, El Solh N, Cuny C, Witte W, Tassios PT, Legakis N, van Leeuwen W, van Belkum A, Vindel A, Laconcha I, Garaizar J, Haeggman S, Olson-Liljequist B, Ransjö U, Coombes G, Cookson B. Harmonization of pulsed-field gel electrophoresis protocols for epidemiological typing of strains of methicillin-resistant *Staphylococcus aureus*: a single approach developed by consensus in 10 European laboratories and its application for tracing the spread of related strains. *J Clin Microbiol.* 2003 Apr;41(4):1574-85.
19. Isenberg HD. *Clinical Microbiology procedures handbook.. Identification of commonly isolated aerobic gram-positive bacteria.* American Society for Microbiology, Washington D.C. Ed. 1992; Vol1: 1.20
20. National Committee for Clinical Laboratory Standards . Performance standards for antimicrobial susceptibility testing. Informational supplement. 2002;M100-S12. NCCLS, Villanova, PA.
21. Claus H, Cuny C, Pasemann B, Witte W. A database system for fragment patterns of genomic DNA of *Staphylococcus aureus*. *Zentralbl Bakteriol.* 1998 Jan;287(1-2):105-16.
22. Braulke C, Heuck D, Witte W. Ergebnisse der Tätigkeit des Nationalen Referenzzentrums für Staphylokokken im Jahr 1998. *Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz.* 1999;42:499-506.
23. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant *Staphylococcus aureus* with reduced sensitivity to glycopeptides. *J Clin Microbiol.* 2001 Oct;39(10):3586-90.
24. Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *J Clin Microbiol.* 2000 Mar;38(3):1032-5.
25. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. *J Clin Microbiol.* 1995 Sep;33(9):2233-9..
26. Coello R, Glynn JR, Gaspar C, Picazo JJ, Fereres J. Risk factors for developing clinical infection with methicillin-resistant *Staphylococcus aureus* (MRSA) amongst hospital patients initially only colonized with MRSA. *J Hosp Infect.* 1997 Sep;37(1):39-46.
27. Merrer J, Santoli F, Appere de Vecchi C, Tran B, De Jonghe B, Outin H. "Colonization pressure" and risk of acquisition of methicillin-resistant *Staphylococcus aureus* in a medical intensive care unit. *Infect Control Hosp Epidemiol.* 2000 Nov;21(11):718-23.
28. Witte W, Kresken M, Braulke C, Cuny C. Increasing incidence and widespread dissemination of methicillin-resistant *Staphylococcus aureus* (MRSA) in hospitals in central Europe, with special reference to German hospitals. *Clin Microbiol Infect.* 1997 Aug;3(4):414-422.
29. Skov R, Larsen AR, Bücher S, Stegger M, Klennush T, Monnet D. National surveillance on methicillin resistant *Staphylococcus aureus* in Denmark, 1999-2003. Abstract 0264. 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, April 2 - 5, 2005.
30. Strommenger B, Cuny C, Werner G, Witte W. Obvious lack of association between dynamics of epidemic methicillin-resistant *Staphylococcus aureus* in central Europe and agr specificity groups. *Eur J Clin Microbiol Infect Dis.* 2004 Jan;23(1):15-9.
31. Frazee BW, Lynn J, Charlebois ED, Lambert L, Lowery D, Perdreaux-Remington F. High prevalence of methicillin-resistant *Staphylococcus aureus* in emergency department skin and soft tissue infections. *Ann Emerg Med.* 2005 Mar;45(3):311-20.
32. Hanssen AM, Fossum A, Mikalsen J, Halvorsen DS, Bukholm G, Sollid JU. dissemination of community-acquired methicillin-resistant *Staphylococcus aureus* clones in northern Norway: sequence types 8 and 80 predominate *J Clin Microbiol.* 2005 May;43(5):2118-24.

ORIGINAL ARTICLES

Surveillance report

SURVEILLANCE OF ANTIMICROBIAL RESISTANCE OF INVASIVE PATHOGENS: THE ESTONIAN EXPERIENCES

K Lõivukene¹, K Kermes¹, E Sepp², V Adamson³, P Mitt³, Ü Kallandi⁴, K Otter⁴, P Naaber¹, on behalf of the European Antimicrobial Resistance Surveillance System, Estonian Study Group*

The aim of the present study was to evaluate the needs for surveillance of invasive Gram-negative pathogens in Estonia. The antimicrobial susceptibility data of invasive isolates of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Klebsiella spp.*, *Escherichia coli*, *Staphylococcus aureus*, *Streptococcus pneumoniae* and *enterococci* were collected in accordance with EARSS (European Antimicrobial Resistance Surveillance System) protocols. Despite the higher rate of Gram positive pathogens, their resistance was low in contrast to the elevated resistance established for Gram negative pathogens. The higher resistance to antimicrobials was particularly associated with *A. baumannii* and *P. aeruginosa*. Also, the proportion of extended-spectrum beta-lactamases (ESBL)-producing strains was 23% among *Klebsiella spp.* and 3.6% among *E. coli*. The inclusion of invasive Gram negative pathogens in antimicrobial resistance surveillance provides useful information concerning local pathogen susceptibility, as well as for the empirical treatment of suspected infections.

Euro Surveill 2006;11(1): 47-9

Published online February 2006

Key words: antimicrobial susceptibility, Estonia, invasive pathogens

Introduction

The epidemiology of invasive bloodstream pathogens has changed dramatically over the years [1-3]. The change in the incidence and epidemiology of infecting organisms has also brought about an increase in resistance to many antibiotic compounds [2,4,5]. Despite numerous publications on antimicrobial resistance, the comparison and evaluation of data is difficult, as the patient groups, sampling sites and infections involved in each study were different.

In order to overcome these problems, the European Antimicrobial Resistance Surveillance System (EARSS) began the collection of standardised data about the resistance of invasive isolates, focusing especially on Gram positive pathogens. Until 2005, information about Gram negative bacteria was available only in case of *E. coli* [6]. In addition, from the summer of 2005 onwards, data are being collected on *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* [6]. Infections with Gram negative bacteria still constitute a topical problem in patients with invasive infections, which are quite frequent in Europe [7-13].

1. Laboratory of Clinical Microbiology, United Laboratories of Tartu University Clinics, Tartu, Estonia
 2. Department of Microbiology, University of Tartu, Estonia
 3. Infection Control Service, Tartu University Clinics, Tartu, Estonia,
 4. AstraZeneca, Estonia

The high degree of cultural, economic and social diversity, as well as the habits of antibiotic usage in European countries, probably influence the spectrum and susceptibility pattern of invasive pathogens, for example, the variation in the number of antibiotic prescriptions per 1000 population as well as the choice/preference of different antibiotic groups between the northern, central and eastern European countries was found [14,15,16,17]. Treatment and infection control guidelines also vary between countries [17]. Hence the usefulness of the resistance markers traditionally used in surveillance (such as methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant enterococci, and penicillin-nonsusceptible *Streptococcus pneumoniae*) may have limited value for empirical antibiotic therapy and the evaluation of resistance trends in some regions. The aim of this study was to use the EARSS protocols and network to introduce surveillance of the resistance of invasive Gram negative pathogens and to evaluate their resistance and importance, in addition to studying the pathogens traditionally dealt with by EARSS.

Methods

The antimicrobial susceptibility data of invasive (blood and cerebrospinal fluid) non-duplicated isolates of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Klebsiella spp.*, *Escherichia coli*, *S. aureus*, *S. pneumoniae* and enterococci were collected between March and December 2004 at ten Estonian hospitals participating in EARSS. Since these hospitals include all hospitals performing blood cultures, the catchment population is almost all of Estonia's 1.4 million population. Two culture systems were used: Bactec (Becton Dickinson, USA, six hospitals) and Signal System (Oxoid, UK, four hospitals). For background data about the hospitals, number of samples and percentage of positive cultures and their nomenclature (non-duplicated analyses only) was collected from January to December 2004.

Gram negative pathogens were tested for meropenem, ceftazidime, cefepime, ampicillin/sulbactam, piperacillin/tazobactam, amikacin and ciprofloxacin by E-test (AB Biodisk, Solna, Sweden), according to the manufacturer's instructions. In order to determine extended spectrum betalactamase (ESBL) producers, an E test with ceftazidime and ceftazidime combined with clavulanic acid was used. The susceptibility of Gram positive bacteria was established on the basis of EARSS protocols [6].

The study protocol was approved by the ethics committee of the Estonian Institute of Experimental and Clinical Medicine (2004).

TABLE 1

Spectrum of invasive pathogens isolated in Estonia, January-December 2004

Pathogens (n=1315)	Total	Percentage
Gram negative pathogens	433	33%
<i>E. coli</i>	174	13.2
<i>Enterobacteriaceae</i>	87	6.6
<i>Klebsiella spp.</i>	61	4.6
Gram negative nonfermenters	48	3.7
<i>P. aeruginosa</i>	36	2.7
<i>A. baumannii</i>	27	2
Gram positive pathogens	824	62.7%
CONS	470	35.7
<i>S. aureus</i>	113	8.6
Streptococci	88	6.7
Enterococci	76	6
<i>S. pneumoniae</i>	49	3.7
Gram positive aerobic rods	28	2
Anaerobes	19	1.5
Pathogenic fungi	39	3

Results

Ten hospitals with between 160 and 942 beds (mean 487) and a total of between 48 291 and 272 169 patient days (total 1 297 246) per year participated in the prospective study. The number of collected samples (blood bottles) per 100 patient days varied from 0.1 to 3.2 (median 1.6 per 100 patient days). In total, 19 648 invasive samples were examined and 1315 non-duplicate invasive isolates were isolated from blood and cerebrospinal fluid in 2004 [TABLE 1]. The median proportion of positive samples was 12% (ranges 4.6-16.4%).

The majority were coagulase-negative staphylococci (CONS, 35.7%) followed by *E. coli* (13.2%) and *S. aureus* (8.6%). Among the Gram negatives, other Enterobacteriaceae accounted for 6.6%, *Klebsiella spp.* 4.6%, other Gram negative non-fermenters 3.7%, *P. aeruginosa* 2.7% and *A. baumannii* 2%. Among the Gram positives, the share of *S. pneumoniae* was 3.7%, the share of enterococci 6% and the share of other streptococci 6.7%.

A subset of 216 Gram negative pathogens were collected during the study period, including 117 *E. coli*, 56 *Klebsiella spp.*, 29 *P. aeruginosa*, and 14 *A. baumannii* strains [TABLE 2]. The isolates of *E. coli* and *Klebsiella spp.* were susceptible to meropenem and amikacin, resistance to ciprofloxacin was 3% and 11% respectively. The higher resistance to antimicrobials was associated particularly with *A. baumannii* and *P. aeruginosa*. Also, the proportion of ESBL-producing strains was 23% among *Klebsiella spp.* and 3.6% among *E. coli*.

TABLE 2

MIC_{50/90} values and percentage of susceptibility of *A. baumannii*, *P. aeruginosa*, *Klebsiella spp.*, and *E. coli* invasive strains isolated in Estonian hospitals, March-December 2004

Antibiotic	Pathogen MIC _{50/90} (% of susceptibility)			
	<i>A. bau- mannii</i> N=14	<i>P. aerugi- nosa</i> N=29	<i>Klebsiella</i> <i>spp.</i> N=56	<i>E. coli</i> N=117
Ampicillin sulbactam	4/16 (64)	ND	ND	ND
Piperacillin tazobactam	ND	6/64 (89)	ND	ND
Cefepime	6/16 (71.4)	ND	ND	ND
Ceftazidime	ND	1.5/8 (91.4)	ND	ND
Meropenem	1.5/4 (100)	1/6 (86)	0.032/0.064 (100)	0.023/0.032 (100)
Amikacin	3/256 (78.6)	3/12 (96.6)	2/3 (98)	2/3 (100)
Ciprofloxacin	ND	0.19/6 (83)	0.032/1 (89)	0.016/0.047 (96.7)

Overall antimicrobial resistance among major bloodstream pathogens in Estonia was relatively low in the case of Gram positive indicator pathogens. No penicillin non-susceptible *S. pneumoniae* were found. The proportion of methicillin-resistant *S. aureus* was 4%, and the proportion of vancomycin non-susceptible enterococci was 1.6% (one strain with MIC value 6 mL).

Discussion

The most frequent invasive pathogens were coagulase-negative staphylococci, *E. coli* and *S. aureus*. Similarly, the five most common pathogens in other European studies were also *E. coli*, *S. aureus*, CONS, enterococci and *Klebsiella spp.* [8,10,11]. In our study, the ratio of Gram positive to Gram negative pathogens was 1.9. According to the data from the literature, Gram negative bacilli were the predominant pathogens in the 1970s; in recent decades, Gram positive cocci, especially CONS, have emerged as a more frequent cause of invasive infections [1-3,18]. The increase in CONS could be attributed to the increasing proportion of neonatal and haematological patients. However, the quantity of

true infections and contamination is impossible to evaluate, since harmonised exclusion algorithms for common skin contaminants are not used in our study or other published studies.

Antimicrobial resistance among Estonian invasive pathogens was relatively low, more closely resembling northern European than southern and eastern European regions [19]. This is especially true in the case of Gram positive pathogens [6-8,10,20]. However, the isolation of the first strains of VRE and the recent increase of MRSA cases in some Estonian hospitals may predict an emergence of resistance [6].

Despite the relatively lower frequency of *A. baumannii* and *P.aeruginosa*, the higher resistance to antimicrobials was particularly associated with these pathogens, and this is similar to the experience of other authors [7-10,12,21]. A comparison of the data from the SENTRY and MYSTIC study with those from Estonia shows some differences in antibiotic choice and study criteria and the limitations of pooling those data. In general, Gram negative invasive isolates from Estonian hospitals were at least as sensitive as the European average [6,8].

The use of invasive strains in resistance surveillance has some advantages. The inclusion criteria are clear, and since colonisation and contamination are excluded (except CONS), these strains are real pathogens, making the data more comparable. Since the number of strains is relatively small, more expensive but also more informative methods, such as MIC detection and typing, can be used. However, different sampling habits between different hospitals and countries may influence the quality of the data [6]. It is also not clear how the resistance of invasive strains represents the overall situation of proportions and trends. Today, few studies with controversial results [13,19,22] are available offering comparative information about the aetiology and susceptibility of both invasive as well as non-invasive pathogens.

It is a common view that resistance surveillance should focus mainly on MRSA and other Gram positive organisms. In our situation, however, where high resistance and therapy failures are frequently associated with Gram negative bacteria (such as *Klebsiella*, *Acinetobacter* and *Pseudomonas*), the inclusion of these pathogens for antimicrobial resistance surveillance provides useful information [6,23].

Thus we can conclude that due to interstate and regional (for example, eastern, central and northern Europe) differences in pathogens' profile and susceptibility pattern, international conventional surveillance systems should be modified according to local situations, and additional diagnostic methods should be included if necessary.

* Members of the European Antimicrobial Resistance Surveillance System, Estonian Study Group: K Abel, M Ivanova, M Jürna, N Kamõnina, K Kirs, V Kõlesnikova, Ü Laaring, H Mägi, R Männik, G Nemtseva, L Pirozkova, K Pärõ, S Rudenko, A Rõõm, T Timmas, R Voiko.

Acknowledgements

The study was supported by AstraZeneca, the Baltic Task Force Project and the Estonian Science Foundation (Grant No. 5826 and No. 6458).

References

1. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. *J Antimicrob Chemother.* 1998 Jun;41 Suppl D:13-24.
2. Karchmer A-W. Nosocomial Bloodstream Infections: Organisms, Risk Factors, and Implications. *Clin Infect Dis.* 2000 Sep;31 Suppl 4:S139-43.

3. Karłowsky JA, Jones MJ, Draghi DC, Thornsberry C, Sahn DF, Volturo GA. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. *Ann Clin Microbiol Antimicrob.* 2004; 3:7. <http://www.ann-clinmicrob.com/content/3/1/7>. Accessed 22 October 2005.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest.* 1999 Feb;115(2):462-74.
5. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, et al. *Pseudomonas aeruginosa* bacteraemia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. *Clin Infect Dis.* 2003 Sep 15;37(6):745-51.
6. European Antimicrobial Resistance Surveillance System. <http://www.earss.rivm.nl>. Accessed 22 October 2005.
7. Bouza E, Pérez-Molina J, Muñoz P on behalf of the Cooperative Group of the European Study Group on Nosocomial Infections (ESGNI). Bloodstream infections in Europe. Report of ESGNI-001 and ESGNI-002 Studies. European Society of Clinical Microbiology and Infectious Diseases. Accessed at <http://www.esgni.org/Esgni01-02.html>.
8. Fluit A, Jones M-E, Schmitz F-J, Acar J, Gupta R, Verhoef J, and the SENTRY Hospital Participants Group. Antimicrobial Susceptibility and Frequency of Occurrence of Clinical Blood Isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. *Clin Infect Dis.* 2000 Mar;30(3):454-60.
9. Assadian O, Apfalter P, Assadian A, Makristathis A, Daxboeck F, Koller W, et al. Antimicrobial susceptibility profiles of clinically relevant blood culture isolates from nine surgical intensive care units, 1996-2000. *Eur J Clin Microbiol Infect Dis.* 2002 Oct;21(10):743-7.
10. Luzzaro F, Viganò EF, Fossati D, Grossi A, Sala A, Sturla C, et al. AMCLI Lombardia Hospital Infectious Study Group. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. *Eur J Clin Microbiol Infect Dis.* 2002 Dec;21(12):849-55.
11. Velasco E, Byington R, Martins CA, Schirmer M, Dias LM, Goncalves VM. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center. *Eur J Clin Microbiol Infect Dis.* 2003 Mar;22(3):137-43.
12. Daxboeck F, Assadian O, Blacky A, Koller W, Hirschl AM. Resistance of gram-negative non-fermentative bacilli causing bloodstream infection, Vienna, 1996-2003. *Eur J Clin Microbiol Infect Dis.* 2004 May;23(5):415-6.
13. Jones ME, Karłowsky JA, Draghi DC, Thornsberry C, Sahn DF, Bradley JS. Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. *Eur J Clin Microbiol Infect Dis.* 2004 Jun;23(6):445-55.
14. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet.* 2005 Feb 12-18;365(9459):579-87.
15. Vander Stichele R, Elseviers M, Ferech M, Blot S, Goossens H, and the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): data collection performance and methodological approach. *Br J Clin Pharmacol.* 2004 Oct;58(4):419-28.
16. Cizman M, Beovic B, Krcmery V, Barsic B, Tamm E, Ludwig E, et al. Antibiotic policies in Central Eastern Europe. *Int J Antimicrob Agents.* 2004 Sep;24(3):199-204.
17. Mölstad S, Stålsby Lundborg C, Karlsson A-K, Cars O. Antibiotic prescription rates vary markedly between 13 European countries. *Scand J Infect Dis.* 2002;34(5):366-71.
18. Hadziyannis SA, Stephanou I, Dimarogona K, Pantazatou A, Fourkas D, Filiagouridis D, et al. Blood culture results during the period 1995-2002 in a Greek tertiary care hospital. *Clin Microbiol Infect.* 2004 Jul;10(7):667-70.
19. Unal S, Masterton R., Goossens H. Bacteraemia in Europe - antimicrobial susceptibility data from the MYSTIC surveillance programme. *Int J Antimicrob Agents.* 2004 Feb;23(2):155-63.
20. Reynolds R, Potz N, Colman M., Williams A, David Livermore D, MacGowan A on behalf of the BSAC Extended Working Party on Bacteraemia Resistance Surveillance. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. *Antimicrob Chemother.* 2004 Jun;53(6):1018-32
21. Sörberg M, Farra A, Ransjö U, Gårdlund B, Rylander M, Settergren B, et al. Different trends in antibiotic resistance rates at a university teaching hospital. *Clin Microbiol Infect.* 2003 May;9(5):388-96.
22. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. *Microbiol Immunol Infect.* 2004 Jun;37(3):185-91.
23. Lõivukene K, Sepp E, Adamson V, Kallandi Ü, Otter K, Mägi H, Naaber P, et al. *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* - their importance and antibiotic susceptibility in Estonian intensive care units (in Estonian). *Estonian Physician.* 2004;83:526-534.